PRNB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PRNB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Principia Biopharma's enterprise value is $3,023.44 Mil. Principia Biopharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 was $-67.19 Mil. Therefore, Principia Biopharma's EV-to-EBITDA for today is -45.00.
The historical rank and industry rank for Principia Biopharma's EV-to-EBITDA or its related term are showing as below:
During the past 4 years, the highest EV-to-EBITDA of Principia Biopharma was 234.60. The lowest was -44.56. And the median was -18.34.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-25), Principia Biopharma's stock price is $100.05. Principia Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2020 was $-2.410. Therefore, Principia Biopharma's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Principia Biopharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Principia Biopharma Annual Data | |||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | |||||
EV-to-EBITDA | - | - | 27.17 | -20.11 |
Principia Biopharma Quarterly Data | |||||||||||||
Dec16 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | |
EV-to-EBITDA | Get a 7-Day Free Trial | 79.03 | -24.82 | -20.11 | -18.81 | -22.59 |
For the Biotechnology subindustry, Principia Biopharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Principia Biopharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Principia Biopharma's EV-to-EBITDA falls into.
Principia Biopharma's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 3023.444 | / | -67.194 | |
= | -45.00 |
Principia Biopharma's current Enterprise Value is $3,023.44 Mil.
Principia Biopharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-67.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Principia Biopharma (NAS:PRNB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Principia Biopharma's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 100.05 | / | -2.410 | |
= | At Loss |
Principia Biopharma's share price for today is $100.05.
Principia Biopharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.410.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Principia Biopharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Patrick Machado | director | 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107 |
Stefani Wolff | officer: Chief Development Officer | C/O PRINCIPIA BIOPHARMA INC., 400 EAST JAMIE COURT, SUITE 302, SOUTH SAN FRANCISCO CA 94080 |
Daniel J. Becker | director | C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036 |
Martin Babler | director, officer: President, CEO | C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
Dolca Thomas | officer: Chief Medical Officer | C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Simeon George | director | 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428 |
Shawn Tomasello | director | C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085 |
Alan Colowick | director | C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063 |
Shao-lee Lin | director | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
David M Goldstein | officer: Chief Scientific Officer | C/O PRINCIPIA BIOPHARMA INC. 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080 |
Roy C. Hardiman | officer: Chief Business Officer | C/O PHARMACYCLICS, INC. 995 EAST ARQUES AVENUE SUNNYVALE CA 94085 |
Christopher Y Chai | officer: Chief Financial Officer | 2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Bvf Gp Holdings Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Ii Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
From GuruFocus
By Marketwired Marketwired • 11-24-2020
By Marketwired Marketwired • 08-18-2020
By Marketwired Marketwired • 08-07-2020
By [email protected] insider • 08-21-2020
By Marketwired Marketwired • 06-12-2020
By [email protected] insider • 03-06-2020
By PRNewswire PRNewswire • 09-12-2020
By Marketwired Marketwired • 08-17-2020
By PRNewswire PRNewswire • 08-18-2020
By [email protected] insider • 06-26-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.